EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS4590-TPS4590
◽
2020 ◽
Vol 37
(1)
◽
pp. e9-e13
2018 ◽
Vol 36
(26)
◽
pp. 2743-2744
◽
2021 ◽
Vol 77
(18)
◽
pp. 3298